Last reviewed · How we verify
NCT02938793
Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors
Phase 2 trial testing Durvalumab in Cancer in 92 participants. Terminated before completion.
17 September 2025
Quick facts
| Lead sponsor | Prisma Health-Upstate |
|---|---|
| Phase | Phase 2 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 92 |
| Start date | 1 December 2016 |
| Primary completion | 17 September 2025 |
| Estimated completion | 17 September 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Durvalumab — full drug profile →
- Tremelimumab (TREMELIMUMAB) — full drug profile →
Conditions studied
- Cancer — all drugs for Cancer →
- Rare Disease — all drugs for Rare Disease →
Sponsor
Prisma Health-Upstate — full company profile →
Who can join
18 and older, any sex, with Cancer or Rare Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an investigator initiated single institution, open-label study to evaluate the antitumor activity, safety, and tolerability of durvalumab in combination with tremelimumab in subjects with select advanced rare solid tumors.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Combination therapy with PD-1/PD-L1 blockade: An overview of ongoing clinical trials.
Johnson CB, Win SY. · · 2018 · cited 26× · PMID 29632719 · DOI 10.1080/2162402x.2017.1408744 -
The Comprehensive "Omics" Approach from Metabolomics to Advanced Omics for Development of Immune Checkpoint Inhibitors: Potential Strategies for Next Generation of Cancer Immunotherapy.
Yoon SJ, Lee CB, Chae SU, Jo SJ, et al · · 2021 · cited 13× · PMID 34203237 · DOI 10.3390/ijms22136932 -
A Phase II Study of Durvalumab in Combination with Tremelimumab in Patients with Rare Cancers.
Edenfield WJ, Edenfield WJ, Chung K, O'Rourke M, et al · · 2021 · cited 9× · PMID 33893692 · DOI 10.1002/onco.13798 -
Revolutionizing cancer treatment: the rise of personalized immunotherapies.
Fayyaz A, Haqqi A, Khan R, Irfan M, et al · · 2024 · cited 6× · PMID 39692978 · DOI 10.1007/s12672-024-01638-1 -
Basket trials in rare diseases: a systematic review of current practices, methodological challenges, and future directions.
Khazen W, Corriol-Rohou S, Evangelista T, Valent A, et al · · 2025 · cited 1× · PMID 41225614 · DOI 10.1186/s13023-025-04048-w
Verify or expand the search:
- PubMed search for NCT02938793
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Durvalumab
Trials testing the same drug.
- NCT07507968 — TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma · Phase 2 · not yet recruiting
- NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle · Phase 2 · not yet recruiting
- NCT07339059 — Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Ce · Phase 2 · recruiting
- NCT07531095 — Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) · Phase 1 · not yet recruiting
- NCT07459634 — A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC · Phase 2 · not yet recruiting
Other recruiting trials for Cancer
Currently open trials in the same condition.
- NCT07390045 — Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors · NA · recruiting
- NCT07528547 — Hypersight and Ethos In Pediatric Radiotherapy · NA · recruiting
- NCT07481890 — Feasibility and Efficacy of the EMDR Toolbox Method in Cancer Patients. · NA · recruiting
- NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations · NA · recruiting
- NCT07305740 — On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety · NA · recruiting
Other Prisma Health-Upstate trials
Trials by the same sponsor.
- NCT07202039 — Electronic Cigarettes as a Harm Reduction Strategy Among People With Opioid Use Disorder on Buprenorphine · NA · not yet recruiting
- NCT07375212 — VAPorized Administration of Bumetanide for Outpatient Relief in Heart Failure · Phase 4 · withdrawn
- NCT07102615 — Intracervical Vasopressin · Phase 4 · recruiting
- NCT07101250 — Preoperative Acetazolamide · Phase 4 · recruiting
- NCT06874413 — Targeted Prehabilitation With Physical Exercise and Inspiratory Muscle Training for Elderly Frail Patients Prior to Vent · NA · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02938793 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Prisma Health-Upstate
- Last refreshed: 23 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02938793.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing